1. [Malignant peripheral nerve sheath tumor associated with clear cell renal cell carcinoma - case report].
- Author
-
Gryglicka B, Węgrzyn-Szkutnik I, Milanowski J, Mandziuk S, Grzybowska-Szatkowska L, Surdyka D, Czekajska-Chehab E, and Zdunek M
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms secondary, Chemoradiotherapy, Adjuvant, Disease Progression, Female, Humans, Lumbar Vertebrae, Lung Neoplasms secondary, Lung Neoplasms therapy, Middle Aged, Neoplasm Recurrence, Local therapy, Pleural Neoplasms secondary, Spinal Neoplasms secondary, Thoracic Vertebrae, Carcinoma, Renal Cell secondary, Carcinoma, Renal Cell surgery, Kidney Neoplasms surgery, Neoplasms, Second Primary secondary, Neoplasms, Second Primary surgery, Nerve Sheath Neoplasms therapy, Neurilemmoma therapy
- Abstract
Malignant peripheral nerve sheath tumor (MPNST) is a rare malignant counterpart to benign neurogenes tumors such as schwannomas and neurofibromas and account for approximately 5-10 % of all soft tissue sarcomas. This neoplasm is also referred to older designations as a malignant schwannoma, malignant neurilemmoma or neurogenic sarcoma. A patient was a woman of 59 years old with a diagnosed malignant neurilemmoma, treated since 1993. Operated several times and subjected to radiotherapy due to the local recurrence of the tumors located in the soft tissues of the back until 2002; Treated with chemotherapy (doxorubicin) and operated due to a lung metastases. The therapy resulted in a total remission that lasted 12 months. In 2004 a new small tumor was diagnosed in the right lung, which had been followed up until 2006. The patient did not give permission to a second surgery, treated with ifosfamide. In 2006 she was operated for renal cell carcinoma of the left kidney. In 2009, due to a following progression of neurilemmoma and a worsening overall condition, she was subsequently treated with a combination of gemcitabine and docetaxel. The treatment resulted in a slight improvement, but was stopped due to complications (pancytopenia). In 2010 another progression of the disease occurred, which resulted in pleural metastases and osteolytic lesions in the vertebrae (Th6 and L2).
- Published
- 2012